MRD-Guided Azacitidine May Delay Relapse in AML, MDS

by | Apr 2, 2026 | Health

Spread the love
New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments